



Paul Kehoe, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

19th July 2022

PQ: 35931/22

To ask the Minister for Health when the cost of the medication cariban which is used to treat hyperemesis in pregnancy will be reduced; and if he will make a statement on the matter. -Paul Kehoe

Dear Deputy Kehoe,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 35931/22), which you submitted to the Minister for Health for response.

Cariban (doxylamine / pyridoxine) is an unlicensed product that is not reimbursable under GMS and Community Drug Schemes. There is no agreed reimbursement price in place for this Exempt Medicinal Product (EMP). As such, the HSE have no ability to manage the price for a product outside of Schemes.

Only licensed products are added to the formal GMS Reimbursement List in line with the Health (Pricing and Supply of Medical Goods) Act 2013. It is a matter for the Marketing Authorisation Holder to apply for licensing in Ireland through the Health Products Regulatory Authority (HPRA).

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Suzanne Doyle'.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service